

From: [Lukas, Aaron](#)
To: [Trials](#)
Cc: [Boezi, Mark](#); [Coblentz, W. Blake](#); [James Murphy](#); rmurphy@polsinelli.com; jballs@polsinelli.com; [IPDocketing](#)
Subject: RE: IPR2023-01439
Date: Tuesday, June 4, 2024 4:11:39 PM

CAUTION: This email has originated from a source outside of USPTO. **PLEASE CONSIDER THE SOURCE** before responding, clicking on links, or opening attachments.

Inolx appreciates the Board's guidance, and agrees to waive the requirement for a conference call. Inolx intends to file its Motion to Amend in due course per the schedule in this proceeding. Counsel for Symrise similarly confirmed that no conference call is required.

Best regards,
Aaron



Aaron S. Lukas, Ph.D.
Co-Chair, Hatch-Waxman & Biologics Practice
Registered Patent Attorney
1200 19th Street, NW | Washington, DC 20036
P: 202-912-4823 F: 202-618-4829
[Email](#) | [Bio](#) | [LinkedIn](#) | [Map](#) | cozen.com

From: Trials <Trials@USPTO.GOV>
Sent: Tuesday, June 4, 2024 1:29 PM
To: Lukas, Aaron <ALukas@cozen.com>; Trials <Trials@USPTO.GOV>
Cc: Boezi, Mark <MBoezi@cozen.com>; Coblentz, W. Blake <WCoblentz@cozen.com>; James Murphy <jpmurphy@polsinelli.com>; rmurphy@polsinelli.com; jballs@polsinelli.com; IPDocketing <ipdocketing@cozen.com>
Subject: RE: IPR2023-01439

****EXTERNAL SENDER****

Counsel:

In light of the parties' familiarity with the Motion to Amend process in related IPR2023-01035 (Paper 11), the requirement for a conference call to discuss Patent Owner's Motion to Amend under 37 C.F.R. § 42.121(a) in this proceeding is waived.

If, however, the parties would still like to have a call, the panel is available on June 10 at 2 pm ET. Please respond to this e-mail to advise whether such a call is needed.

Regards,

Esther Goldschlager
Supervisory Paralegal Specialist
Patent Trial & Appeal Board
U.S. Patent & Trademark Office

From: Lukas, Aaron <ALukas@cozen.com>

Sent: Monday, June 3, 2024 4:26 PM

To: Trials <Trials@USPTO.GOV>

Cc: Boezi, Mark <MBoezi@cozen.com>; Coblentz, W. Blake <WCoblentz@cozen.com>; James Murphy <jpmurphy@polsinelli.com>; rmurphy@polsinelli.com; jballs@polsinelli.com

Subject: IPR2023-01439

CAUTION: This email has originated from a source outside of USPTO. **PLEASE CONSIDER THE SOURCE** before responding, clicking on links, or opening attachments.

Trials:

I am lead counsel for Patent Owner in IPR2023-01439. Pursuant to the Scheduling Orders (Paper 7), I write to request a conference with the Board concerning a motion to amend that Patent Owner intends to file, as well as Patent Owner's intent to request preliminary guidance from the Board on its motion.

I have conferred with counsel for Petitioners, and the parties are available for a conference on the following dates and times:

- June 6: 9am-2pm and 3-4pm
- June 7: 9am-2pm
- June 10: 9am-11am and 12pm-4pm
- June 12: 9am-5pm

Respectfully,
Aaron Lukas



Aaron S. Lukas, Ph.D.
Co-Chair, Hatch-Waxman & Biologics Practice
Registered Patent Attorney
1200 19th Street, NW | Washington, DC 20036
P: 202-912-4823 F: 202-618-4829
[Email](#) | [Bio](#) | [LinkedIn](#) | [Map](#) | cozen.com

Notice: This communication, including attachments, may contain information that is confidential and protected by the attorney/client or other privileges. It constitutes non-public information intended to be conveyed only to the designated recipient(s). If the reader or recipient of this communication is not the intended recipient, an employee or agent of the intended recipient who is responsible for delivering it to the intended recipient, or you believe that you have received this communication in error, please notify the sender immediately by return e-mail and promptly delete this e-mail, including attachments without reading or saving them in any manner. The unauthorized use, dissemination, distribution, or reproduction of this e-mail, including attachments, is prohibited and may be unlawful. Receipt by anyone other than the intended recipient(s) is not a waiver of any attorney/client or other privilege.

Notice: This communication, including attachments, may contain information that is confidential and protected by the attorney/client or other privileges. It constitutes non-public information intended to be conveyed only to the designated recipient(s). If the reader or recipient of this communication is not the intended recipient, an employee or agent of the intended recipient who is responsible for delivering it to the intended recipient, or you believe that you have received this communication in error, please notify the sender immediately by return e-mail and promptly delete this e-mail, including attachments without reading or saving them in any manner. The unauthorized use, dissemination, distribution, or reproduction of this e-mail, including attachments, is prohibited and may be unlawful. Receipt by anyone other than the intended recipient(s) is not a waiver of any

attorney/client or other privilege.